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Abstract
Despite the rapid development of therapeutic modalities for advanced or metastatic 
renal cell carcinoma (mRCC) over the past decade to include traditional immunotherapy, 
such as high-dose interleukin-2 and interferon-α, as well as a number of targeted anti-
angiogenic therapies, mRCC continues to be associated with poor prognosis. Currently, 
immunotherapy has seen tremendous development in the form of immune checkpoint 
inhibition and vaccines at a dizzying pace, which are being studied in mRCC and are 
showing promise as important steps in the management of this disease. With so many 
drugs available to clinicians and patients, properly integrating immunotherapy espe-
cially immune checkpoint blockade (ICB) into the treatment paradigm is challenging. 
Emerging research with additional ICB agents and novel combination strategies is likely 
to further impact clinical decision-making. The further development of biomarkers for 
predicting a response is required to achieve optimal efficacy with these therapeutic 
interventions. This chapter summarizes the current landscape of standard and emerging 
immune therapeutics and other modalities for mRCC.
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1. Introduction
Renal cell carcinoma (RCC) is the most prevalent kidney cancer, with nearly 63,990 cases diag-
nosed and 14,400 deaths in 2017 [1]. Approximately 25–30% of cases are metastatic at diagnosis 
[2] and 20–30% of patients who undergo surgical management for local RCC show metastases 
[3]. Recently, the enhanced comprehension of RCC pathogenesis led to the development of 
von Hippel-Lindau/ hypoxia-inducible factor (VHL/HIF) targeted therapy as the mainstay of 
therapeutic options for advanced RCC patients, improving the survival rates of patients [4]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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However, the current 3-year overall survival rate is yet no more than 40% and a majority of 
patients will die because of the progressed disease [5]. As a consequence, new targets and 
therapies are needed to improve patient outcomes. The rapidly evolving field of immuno-
oncology yields several novel immunotherapeutic agents. Currently, cancer vaccines, adoptive 
T-cell therapy, and immune checkpoint inhibitors (ICIs) are being investigated in advanced 
RCC and are producing durable responses and noteworthy overall survival improvement. 
This chapter mainly introduces the treatment landscape of immune therapeutics for RCC.
2. Immunotherapy
The immune system interacts intimately with tumors over the entire disease process. The 
complex crosstalk between the immune system and cancer cells determines the eventual out-
come, either inhibiting or enhancing tumor development [6]. First, antigen-presenting cells 
(APCs), primarily dendritic cells (DCs), must encounter tumor-associated antigen (TAA), 
which can emerge via the altered protein structure caused by somatic mutations or differen-
tially expressed proteins. The antigen expression pattern needs to be different from that on 
normal cells to avoid immune tolerance. APCs process TAA into peptide fragments, which 
then form a complex with major histocompatibility complex (MHC) class I and II molecules. 
The initial step of T-cell activation is the recognition of antigen presented on the MHC mol-
ecule of APCs by T-cell receptor (TCR). Full T-cell activation also requires a co-stimulatory 
signal by the binding of CD28 on T cell to B7 ligands (CD80 and CD86) on APCs [7].
Multiple feedback mechanisms exert stimulatory or inhibitory effects on T cells, regulating 
immune function and preventing an excessive immune response. These mechanisms include 
immune checkpoint molecules on the surface of T cells and other immune cells such as regulatory 
T (T
reg
) cells and myeloid-derived suppressor cells (MDSCs) [8]. Tumor cells can take advantage 
of these mechanisms to prevent a potential anticancer immune response. RCC usually presents 
prominent immune cell infiltration, including T cells, natural killer (NK) cells, DCs, and mac-
rophages. During early stages, malignant cells can be poor stimulators and become resistant to 
the innate immune response. Later, progressively growing tumors impair the adaptive immune 
response by blocking T-cell signal transduction and function [9]. An increased understanding of 
these processes has enabled the development of immunotherapy for cancer management.
Immunotherapy is defined as excluding cancer by activating the autoimmune response 
against the tumor rather than by attacking the tumor directly. Immunotherapy can induce 
long-lasting anticancer responses owing to the generation of antigen-specific immune mem-
ory, either through memory T-cells or antibodies. Several crucial steps are needed to mount 
an initial effective immune response against tumors [10]. Immune checkpoint blockade dis-
rupts negative immune regulations to enhance immune system activity and boost antitumor 
immune response. Other immunomodulatory therapies such as cytokine therapy and vac-
cines potentiate co-stimulatory pathways or stimulate the innate immunity or interact with 
the immune suppressive tumor microenvironment. The past decade has witnessed the emer-
gence of immunotherapy as an exciting treatment option for different malignancies, including 
RCC. The following sections discuss these in more detail (Figure 1).
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3. Traditional immunotherapy for mRCC
Cytokine therapy, involving IFN-α and IL-2, was the main treatment for mRCC before the 
approval of targeted therapies. IFN-α has antiangiogenic effects, promoting antigen presenta-
tion and dendritic cell maturation. The efficacy of IFN-α for mRCC patients was first reported 
in 1989, and it was confirmed that IFN-α is active [11]. The response rate of IFN-α was 15%, 
with 3–7 months increase in overall survival [12]. However, most responses to IFN-α were 
not long-lasting and rare patients showed complete responses. In addition, side effects such 
as flu-like symptoms and liver toxicity disenabled the long-term use of IFN-α. IL-2 is a potent 
stimulator of T-cell proliferation and differentiation. High dose IL-2 (HD IL-2) was approved 
in 1992 for treatment of mRCC based on an objective response rate (ORR) between 10 and 
20%; many of the responses were durable and continued for a long time [13]. Despite HD IL-2 
having become the preferred treatment, there is a limitation of severe toxicity that can prove 
in various organ systems, most significantly the heart, lungs, kidney, and central nervous 
system. The treatment of cytokine alone has gradually fallen out of favor from the first-line 
setting in the current era of targeted therapy and immunotherapy.
4. Vaccines
Studies on vaccine therapies in mRCC are still ongoing. They mainly focus on the treatment 
of primary tumors rather than prevention. Tumor vaccines have been designed to enhance the 
Figure 1. Immunotherapies under investigation for renal cell carcinoma.
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ability of the immune system to recognize tumor antigens, improve immune microenvironment, 
and trigger strong specific antitumor cell immunity. Currently, clinical trials evaluating various 
vaccines have been conducted, although none has demonstrated an improvement in survival 
thus far. In the future, vaccination approaches will probably be further tailored to the patient’s 
mutanome and tumor-associated antigen profile, with the goal of individualizing treatments 
and, thus, maximizing the potential benefits [14–16].
4.1. AGS-003
AGS-003 is a dendritic cell immunotherapeutic vaccine constructed from autologous blood 
dendritic cells and generated through the electroporation of tumor-derived RNA and CD40 
ligands (CD40L) RNA into host immune cells [17–19]. The tumor RNA-loaded mature den-
dritic cells present patient tumor-specific antigens in T-cells via MHC I. Meanwhile, the 
upregulated CD40L promotes the recruitment of CD8+ T-cell through the regional production 
of IL-12. A phase II study on 21 mRCC patients were treated by a combination therapy of 
AGS-003 with 1 cycle of sunitinib (4 weeks on, 2 weeks off), followed by AGS-003 immu-
notherapy until tumor progression or the end of the study. The median progression-free 
survival (PFS) and overall survival (OS) were 11.2 months and 30.2 months, respectively. 
Remarkably, OS was more than 5 years in 5 patients (24%), with 2 patients achieving durable 
responses for more than 5 years. Of 21 patients, 13 (62%) achieved a clinical benefit (9 with a 
partial response and 4 with stable disease). Treatment with AGS-003 was well tolerated, with 
injection site reactions as the primary adverse event (AE). Based on these promising results, a 
randomized multicenter phase III ADAPT trial is currently under way, to determine whether 
there is an overall survival benefit between AGS-003 and sunitinib in comparison to sunitinib 
alone in mRCC patients undergoing de-bulking nephrectomy (NCT01582672).
4.2. IMA901
IMA901 is a therapeutic vaccine consisting of nine different HLA class I-binding tumor-
associated peptides and one HLA class II-binding tumor-associated peptide. A phase II trial 
investigating the addition of cyclophosphamide (which reduces the T regulatory cells) to 
IMA901 showed that pretreatment with cyclophosphamide prolonged the survival of RCC 
patients compared with IMA901 therapy alone [20]. The majority of adverse events reported 
were local injection site reactions. A phase III trial comparing sunitinib with or without this 
vaccine for mRCC was recently completed. Unfortunately, the OS did not differ significantly 
between the 2 groups [21].
4.3. Modified vaccinia Ankara (MVA-5 T4; TroVax)
MVA-5 T4 was created to stimulate the immune system to destroy cells expressing 5 T4 anti-
gen. The 5 T4 oncofetal antigen is rarely detected in normal adult tissues but is over-expressed 
in kidney cancer [22–24]. A randomized, double-blind phase III study (TRIST trial) assessed 
OS and safety in patients with mRCC [25]. Patients were randomized to MVA-5 T4 (n = 365) or 
placebo (n = 368) in combination with IL-2, IFN-α, or sunitinib. Unfortunately, MVA-5 T4 in 
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combination with IFN-α, IL-2, or sunitinib as a first-line mRCC therapy did not lead to a sig-
nificant difference in OS when compared to the arm without MVA-5 T4 (median 20.1 months 
MVA-5 T4 versus 19.2 months placebo, p = 0.55). The adverse events’ profile was also similar 
between the treatment arms.
4.4. Autologous tumor cell lysate (Reniale)
Principally, autologous tumor cell lysate vaccine active APCs, such as dendritic cells, 
which stimulate a cytotoxic T lymphocyte response toward tumor-associated antigens, 
leading to tumor cell destruction [26–28]. Adjuvant treatment with autologous vaccination 
Reniale (Liponova AG, Hannover, Germany) improved OS in pT3 RCC patients (10-year 
OS rates: 53.6% in vaccine group versus 36.2% in control group; p = 0.022) in a phase III 
study [29]. Additional current studies on nonprotein antigens have been limited. There are 
other ongoing trials involving the DC-based vaccines. Some of the promising ones involve 
the transduction of a fusion gene construct of GM-CSF and carbonic anhydrase IX into 
autologous DCs (NCT01826877), DC/RCC fusion cells in combination with pidilizumab (a 
PD-1 antibody) (NCT01441765), and DCs in combination with cytokine-induced killer cells 
(NCT00862303).
5. Immune checkpoint inhibitors
Peptides derived from tumor-associated antigens are presented via MHC I and II epitopes to 
stimulate CD8+ and CD4+ T cells, respectively [30]. The binding of the T-cell receptor (TCR) to 
the peptide presented by MHC requires further co-stimulatory signals, resulting in the activa-
tion of downstream pathways and secretion of cytotoxic molecules, such as granzyme and 
perforin [31]. Regulatory mechanisms exist to weaken or inhibit immune response, avoiding 
excessive autoimmune response. These breaks in the immune system are often referred to 
as “immune checkpoints,” including PD-1/PD-L1, CTLA4/CD80, and so on. Immune check-
point proteins on CTLs cut off co-stimulatory signals after ligand binding and give rise to 
T-cell anergy and immune suppression. However, immune checkpoint proteins may become 
dysregulated under tumor settings, typically via an overexpression of inhibitory ligands and 
receptors [32]. Blocking these immune checkpoint proteins could improve the capability of 
CTL to mount and maintain an effective T-cell response [32–34].
Over the past decade, immune checkpoint inhibition (ICI) has become a major focus of 
research given its durable response rates and promising survival benefits in various malig-
nancies. Current ICIs include the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) 
antibodies (ipilimumab and tremelimumab), the programmed cell death protein 1 (PD-1) 
antibodies (nivolumab, pembrolizumab, and pidilizumab), and the programmed cell death 
protein ligand 1 (PD-L1) antibodies (atezolizumab, BMS-936559, durvalumab, and avelumab) 
[35] (Figure 2). Multiple clinical trials studying the efficacy of these agents on mRCC are being 
conducted (Table 1), among which nivolumab is the only agent approved for the treatment of 
mRCC by USFDA in 2015 [36].
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Checkpoint inhibitors cause immune-associated adverse events due to hyper-activated T-cell 
response in healthy tissues. The most common adverse reactions include skin rash, fatigue, 
and colitis. The incidence and grade of toxicities caused by CTLA-4 antibodies are greater 
than PD-1/PD-L1-directed monotherapy. Asymptomatic hepatitis and endocrinopathies are 
also occasionally encountered. Other rare, affected organs include eyes, lungs, kidneys, pan-
creas, and the hematologic system [37].
T-cell activation is regulated by various co-stimulatory and inhibitory checkpoints. Both 
agonistic antibodies to activating receptors and blocking antibodies to inhibitory receptors 
can stimulate T-cell activity and are being tested in advanced renal cell carcinoma and other 
solid tumors. Activation of T-cells first requires an antigen-presenting cell (APC), such as a 
dendritic cell, to present an antigen. Here, an APC presents a tumor antigen complexed to 
major histocompatibility complex (MHC) class I to the T-cell via the T-cell receptor (TCR). 
Co-stimulatory signals are also needed at this time. At this point, B7 on an APC can bind 
to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) creating an inhibitory signal, but 
ipilimumab or tremelimumab—CTLA-4 antibodies—can inhibit the inhibitory signal by 
binding to CTLA-4 and promote T-cell activation. Once the activated T-cell is in the tumor 
environment it can recognize the antigen presented by an APC cell in the tumor. At this time, 
the programmed cell death protein 1 (PD-1) receptor can also send an inhibitory signal to the 
T-cell when the receptor binds to programmed cell death 1 ligand 1 (PD-L1), which is often 
expressed on tumor cells. Inhibition of PD-L1 or PD-1 could block that signal. Several PD-1 
inhibitors are under investigation for RCC, including pembrolizumab and pidilizumab, and 
Figure 2. Immune checkpoint inhibitors and agonists being tested in renal cell carcinoma.
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Agent and trial Phase Population Line Design n Response Toxicities Comments Refs
Nivolumab 
(CheckMate 
025/ 
NCT01668784)
III Advanced and 
metastatic RCC
Prior systemic 
therapies: 
antiangiogenic 
therapy
MSKCC risk 
group:
• favorable: 
36%
• intermedi-
ate: 49%
• poor: 15%
Second Open-label, 1:1 randomized 
trial
Arm A: nivolumab 3 mg/kg 
every 2 weeks
Arm B: everolimus 10 mg 
every 2 weeks
821 OS (months)
• nivolumab: 
25
• everolimus: 
19
ORR
• nivolumab: 
25%
• everolimus: 
5%
PFS (months)
• nivolumab: 
4.6
• everolimus: 
4.4
Grade 3–4 
treatment-related 
AEs:
• nivolumab: 19%
• everolimus: 
37%
Hazard ratio 
for death with 
nivolumab = 0.73 
(P = 0.002)
[36]
NCT01354431 II Metastatic RCC
Prior systemic 
therapies: 
Antiangiogenic 
therapy
Second Blinded, 1:1 randomized trial
Arm A: nivolumab 0.3 mg/kg 
every 3 weeks
Arm B: nivolumab 2 mg/kg 
every 3 weeks
Arm C: nivolumab 10 mg/kg 
every 3 weeks
168 OS (months)
• Arm A: 18.2
• Arm B: 25.5
• Arm C: 24.7
ORR
• Arm A: 20%
• Arm B: 22%
• Arm C: 20%
PFS (months)
• Arm A: 2.7
• Arm B: 4.0
• Arm C: 4.2
Grade 3–4 
treatment-related 
AEs:
• Arm A: 5%
• Arm B: 17%
• Arm C: 13%
No dose-
response 
relationship 
was detected as 
measured by PFS
[46]
Agent and trial Phase Population Line Design n Response Toxicities Comments Refs
NCT01358721 Ib Metastatic RCC
Prior systemic 
therapies: not 
specified
First, 
second
Arm A: previously treated 
group
Nivolumab 0.3 mg/kg every 
3 weeks
Arm B: previously treated 
group
Nivolumab 2 mg/kg every 
3 weeks
Arm C: previously treated 
group
Nivolumab 10 mg/kg every 
3 weeks
Arm D: treatment-naive 
group
Nivolumab 10 mg/kg every 
3 weeks
91 OS (months)
• Arm A: 16.4
• Arm B: NR
• Arm C: 25.2
• Arm D: NR
ORR
• Arm A: 9%
• Arm B: 18%
• Arm C: 22%
• Arm D: 13%
Grade 3–4 
treatment-related 
AEs:
• Arm A: 68%
• Arm B: 36%
• Arm C: 57%
• Arm D: 50%
This is the first 
prospective 
translational 
study involving 
analysis of both 
baseline and 
on-treatment 
biopsies in RCC
Clin 
Cancer Res 
2016;22:5461–71.
Nivolumab and 
ipilimumab
I • Previously 
treated or 
treatment-
naive
• All MSKCC 
risk groups 
permitted
First, 
second
Randomized trial of three 
dosing cohorts:
• Arm A: nivolumab 3 mg/
kg plus ipilimumab 1 mg/
kg every 3 weeks × 4
• Arm B: nivolumab 1 mg/
kg plus ipilimumab 3 mg/
kg every 3 weeks × 4
• Arm C: nivolumab 3 mg/
kg ipilimumab 3 mg/
kg every 3 weeks × 4 All 
followed by nivolumab 
3 mg/kg every 2 weeks 
until substantial disease 
progression or toxicity
100 ORR:
• ArmA:38%
• ArmB:40%
PFS at 24 weeks:
• ArmA:54%
• ArmB:68%
Median duration 
of response:
• ArmA: 
67 weeks
• ArmB: 
81 weeks
Treatment in Arm 
C stopped owing to 
toxicity
Grade 3–4 
treatment related 
AEs:
• ArmA:34%
• ArmB:64%
• ArmC:83%
Median OS 
not reached 
with median 
follow-up 
duration ranging 
from 46 to 
90 weeks
J. Clin. Oncol. 
32:5s (Suppl.), 
4504 (2014).
Table 1. Results of immune checkpoint inhibitors in patients with renal cell carcinoma.
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nivolumab was recently FDA approved for patients with RCC who have failed prior antian-
giogenic therapy. PD-L1 inhibitors under investigation include atezolizumab, BMS-936559, 
durvalumab, and avelumab. In addition to inhibitory receptors, several activating receptors 
exist that stimulate T-cell activity, including CD137, CD27, OX40, and GITR. Similarly, sev-
eral agonist antibodies target these receptors which are under investigation for RCC. These 
include urelumab targeting CD137, varlilumab targeting CD27, MEDI10562 targeting OX40, 
and MK-4166 and TRX518 targeting GITR.
5.1. Anti-PD-1 antibodies
PD-1 (CD279) is a cell surface receptor that is expressed on CD4+ and CD8+ T cells as well as 
NK cells and B cells. The expression of PD-1 is increased by several cytokines, such as IL-2, 
IL-7, IL-15, and IL-21. PD-1 belongs to the CD28/CTLA-4 superfamily and has an immunore-
ceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch 
motif (ITSM) which is able to recruit tyrosine phosphatases, anti-SRC homology phosphatase 
(SHP)-1 and SHP-2, to modulate inhibitory signaling [38, 39]. When interacting with its ligands, 
PD-1 suppresses signaling pathways that are involved in T-cell activity [32, 40]. Blockade of 
PD-1 was evaluated and the initial clinical trial demonstrated impressive antitumor response 
in several refractory cancer types, including RCC [41]. Thompson and his colleagues examined 
the expression of PD-1 and PD-L1 in a large number of renal tumors and found PD-1 being 
expressed in 56% of patient tumors with mononuclear cell infiltration. In addition, PD-1 expres-
sion was correlated with advanced tumor stage and worse survival in RCC patients [42–44].
5.1.1. Nivolumab
Nivolumab is a fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody that 
selectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2. Several 
clinical trials of nivolumab have been performed for RCC (Table 1). In a phase I study that 
enrolled 33 patients with mRCC, nivolumab demonstrated an objective response rate of 27% 
and a manageable safety profile; responses were durable [45]. A phase II study enrolled 168 
patients with mRCC who had received previous treatment targeting the vascular endothelial 
growth factor (VEGF) pathway. Nivolumab was dosed at 0.3, 2, or 10 mg/kg every 3 weeks 
and showed antitumor activity with no dose-response relationship observed. There was 
no association between nivolumab dosage and the number of adverse events (AEs), which 
suggested that the incidence of immune-related AEs was limited [46]. Moreover, a random-
ized phase III study (Check Mate 025) evaluating nivolumab (3 mg/kg every 2 weeks) versus 
second-line everolimus (10 mg orally every day, pretreated with antiangiogenic therapy) 
represented a 5.4-month improvement in median OS (25 months and 19.6 months, respec-
tively). Although the ORR was significantly higher in the nivolumab group than in the evero-
limus group (25% versus 5%, odds ratio: 5.98 [95% CI, 3.68–9.72], p < 0.001), PFS was similar 
(4.6 versus 4.4 months, HR 0.88 [95% CI, 0.75–1.03], p = 0.11). This is the first time that an 
immune checkpoint inhibitor has demonstrated an OS benefit when compared with patients 
treated with TKIs for mRCC. The exact mechanism behind the discrepancy between PFS and 
OS is still unknown, and the authors hypothesized that there might be a potential delayed 
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benefit in PFS with nivolumab. Nivolumab was very well tolerated, and a lower proportion 
of patients developed grade 3 or 4 treatment-related AEs (19 and 37%, respectively), includ-
ing fatigue, nausea, and diarrhea, which suggested that the safety profile of nivolumab was 
favorable [36]. Nivolumab was approved by the FDA for pretreated advanced clear-cell RCC 
in November 2015 [36, 41, 46, 47] and is still under investigation as pre- and postoperative 
therapy in mRCC (ADAPTeR) (NCT02446860) and is also being studied in combination with 
other drugs (NCT01472081, NCT02231749, NCT02210117, NCT02335918, and NCT02614456).
5.1.2. Pembrolizumab
Pembrolizumab (formerly known as MK3475 or lambrolizumab), a highly selective human-
ized IgG4 monoclonal antibody against PD-1, has been approved for metastatic melanoma, 
head and neck cancer, and non-small cell lung cancer (NSCLC) mainly as combinational 
therapy. Pembrolizumab is currently being investigated in two randomized phase II trials 
of mRCC patients [48]. A phase I/II study (KEYNOTE-029) involving pembrolizumab plus 
ipilimumab or pegylated interferon alfa-2b (PEGIFN) in patients with advanced melanoma 
and RCC reported an acceptable safety profile [49]. Nowadays, several trials evaluating 
pembrolizumab in combination with various agents with different mechanisms are ongoing 
(NCT02014636, NCT02133742, NCT02348008, NCT02089685, NCT02501096, NCT02619253, 
NCT02298959, NCT02646748, NCT02178722, and NCT02475213). The most common adverse 
events were fatigue, pruritus, and dyspnea. Antitumor activity was observed [50].
5.1.3. Pidilizumab
Pidilizumab (CT-011), another humanized IgG1 kappa monoclonal antibody targeting PD-1, 
is already under evaluation in several hematologic malignancies, including acute myeloid 
leukemia (AML), multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and 
chronic lymphocytic leukemia [51]. There are several efforts under way to assess the agent 
in several solid tumors. As for mRCC, a study is currently under way to assess the combina-
tion of pidilizumab with a novel dendritic cell (DC) fusion cell vaccine (NCT01441765). The 
first group will receive pidilizumab at a dose of 3 mg/kg every 2 weeks intravenously, for a 
total of 4 cycles. The second group will receive infusions of an autologous DC vaccine during 
2–4 cycles of pidilizumab therapy. The noted trial of pidilizumab with an autologous DC 
vaccine is of substantial interest, especially with emerging vaccine-based therapies, such as 
AGS-003 and IMA901 [52–54].
5.2. Anti-PD-L1 antibodies
The encouraging results of PD-1 antibodies in cancer management inspired interest in the 
inhibition of the PD-1 ligands, namely PD-L1. PD-L1 is expressed on a variety of cells, includ-
ing cancer cells, APCs, T-cells, B cells, and myeloid cells. PD-L1 inhibits T-cell proliferation 
and adhesion, as well as cytokine production [17, 55, 56]. PD-L1 expression was detected by 
immune staining in the RCC tissue, and PD-L1 expression by tumor cells (>10%), on infiltrat-
ing lymphocytes (>50%), or the composite of both makers was strongly associated with poor 
prognosis [42, 57].
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5.2.1. Atezolizumab
Atezolizumab (MPDL3280A), a fully humanized monoclonal IgG1 antibody against PD-L1, 
is being evaluated in different cancers, including RCC. It has showed promising results in a 
multicenter phase I trial involving 17 mRCC patients. The ORR was 12% with responses that 
lasted for 4–17 months. Seven patients (41%) had stable disease for more than 24 weeks [55]. 
In another phase Ia study, of the 63 patients with clear-cell RCC that were evaluable, median 
PFS was 5.6 months and median OS was 28.9 months. The ORR was 15% (18% in patients with 
>1 and 9% in those with <1% PD-L1 expression) [58].
5.2.2. BMS-936559
BMS-936559 (MDX-1105) is a fully human monoclonal antibody with high affinity to PD-L1 
and blocks the binding of PD-L1 to both PD-1 and B7.1. In a phase I trial of evaluating BMS-
936559 in 207 patients with different advanced cancer types, 17 patients had mRCC. The study 
showed that 2 of 17 RCC patients had an objective response with response durations for 4 and 
17 months, respectively [59].
5.2.3. Avelumab
Avelumab (MSB0010718C) is a fully human IgG1 monoclonal antibody against PD-L1 and inhib-
its PD-1-PD-L1 interactions. It also has a native Fc region that could induce antibody-dependent 
cell-mediated cytotoxicity (ADCC). In a phase Ib, open-label expansion study, avelumab was 
used in patients with advanced solid tumors and showed an acceptable safety profile [60]. Two 
ongoing trials evaluate avelumab in combination with axitinib (NCT02493751, NCT02684006).
5.2.4. Durvalumab
Durvalumab (MEDI4736) is another human anti-PD-L1 IgG1 monoclonal antibody. It blocks 
PD-L1 binding to PD-1 and CD80, with no binding to PD-L2. ADCC and complement-depen-
dent cytotoxicities are removed by an engineered triple mutation in the Fc domain. A Phase 
1/2, multicenter, open-label study which evaluated the safety and clinical activity of the drug 
in patients with multiple solid tumor types such as non-small cell lung cancer noted a very 
manageable safety profile [61]. There are ongoing trials evaluating durvalumab in combina-
tion with other drugs, including tremelimumab (NCT01975831) and MEDI0680 (AMP-514) 
(a humanized IgG4 monoclonal antibody against PD-1) (NCT02118337) for patients with 
advanced malignancies including RCC.
5.3. Anti-CTLA-4 antibodies
In addition to the PD-1/PD-L1 checkpoint, CTLA-4, an immune checkpoint on the surface of 
cytotoxic T-cells, counteracts the action of the co-stimulatory receptor CD28 and plays a key 
role in the immune response. Both CTLA-4 and CD28 bind identical ligands CD80 and CD86 
(called B7-1 and B7-2), but CTLA4 has a higher affinity for both ligands than CD28. Therefore, 
CTLA4 can antagonize CD28-ligand interactions by competing for ligand binding. In addition, 
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the interaction of CTLA4 with CD80 or CD86 can lead to the endocytosis of these ligands from 
the APC surface into a CTLA4-expressing T-cell (a process called trans-endocytosis). The ligand 
removal impairs the stimulatory capacity of APCs by limiting CD28 signaling and thus inhibits 
T-cell responses [32, 62]. CTLA-4 antibodies were initially tested on colon adenocarcinoma and 
sarcoma in mouse models with noted tumor shrinkage [63]. These encouraging results led to 
the subsequent development of CTLA-4 antibodies, including ipilimumab and tremelimumab.
5.3.1. Ipilimumab
Ipilimumab, an anti-CTLA-4 IgG1 monoclonal antibody, received US FDA approval for 
the treatment of melanoma in 2011 [64, 65]. It has been investigated as monotherapy plus 
nivolumab in metastatic melanoma, with the combination treatment being more effective 
albeit accompanied with significantly more toxicity [66]. Currently, ipilimumab is being 
investigated in mRCC with the combination of nivolumab. In a phase II study of ipilimumab 
in patients with mRCC, 1 of 21 patients had a partial response in the lower dose group (3 mg/
kg followed by 1 mg/kg every 3 weeks). A total of 5 of 40 patients had partial responses at the 
higher dose (3 mg/kg every 3 weeks). AEs were highly significant and associated with tumor 
regression [67]. Ipilimumab has also been investigated in another phase II trial in mRCC; 
however, just 12% of patients achieved a partial response, with a substantial amount of toxici-
ties [67]. Further phase III trials investigating ipilimumab alone (NCT00057889) and in combi-
nation with other drugs have not yet been studied (NCT02231749, NCT02381314).
5.3.2. Tremelimumab
Tremelimumab is another anti-CTLA-4 antibody that is actively being investigated in 
mRCC. Unlike ipilimumab, it is an IgG2 antibody. It is currently being evaluated with dur-
valumab in the treatment of patients with mRCC (NCT01975831).
5.4. Anti-LAG-3 antibodies
Lymphocyte activation gene 3 (LAG-3) is expressed on activated T cells and T
reg
-cells [68]. 
Upon binding to the MHC class II on APCs, LAG-3 induces an inhibitory signal in T-cells [69], 
whereas LAG-3 enhances the suppressive function of T
reg
-cells [70, 71]. Co-expression of LAG-3 
and PD-1 is a marker of exhausted T cells and, therefore, the blockade of both receptors confers 
additive therapeutic activity in preclinical models of chronic infection and cancer [72–74]. In a 
phase I study, a soluble LAG-3-Ig fusion protein (IMP321), which was designed to stimulate 
MHC class II-driven DC activation, has been evaluated in patients with advanced RCC. IMP321 
induced CD8 T-cell activation in patients and disease stabilization with the absence of toxicity 
[75]. Currently, a blocking mAb targeting LAG-3 is being tested in the clinic (NCT01968109).
6. Combined therapy
Preclinical studies point out that the dual blockade of PD-1 and CTLA-4 reduced regula-
tory T
reg
 cell infiltration and increased effector T-cell infiltration and interferon-γ production, 
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achieving a heightened antitumor effect [76]. This approach has demonstrated clinically 
effective synergy from nivolumab plus ipilimumab treatment in patients with advanced 
melanoma [77]. Several studies are ongoing in patients with mRCC on the combinations 
of ICIs with different targets, for example, anti-PD-1 or PD-L1 and anti-CTLA-4 antibodies 
[78, 79], allowing dual/multifaceted manipulation of immunosuppression. A combination of 
nivolumab and ipilimumab has acquired success in patients with treatment naïve or previ-
ously treated RCC (CheckMate 016 study) with an ORR of about 40% [80] these provided the 
rationale for a phase III trial comparing this combination with sunitinib in treatment-naïve 
patients (CheckMate 214, NCT02231749).
Emerging evidence suggests that antiangiogenic therapies may have immune-modulatory 
effects such as the enhancement of cytotoxic T-cell trafficking and infiltration in addition to 
their known direct antiangiogenic effects, possibly potentiating the effectiveness of checkpoint 
inhibitors when administered concurrently [81]. Based on this rationale, several clinical stud-
ies are ongoing in patients with mRCC under the combinations of ICIs and VEGF pathway 
inhibitors (Table 2) [78, 79]. While a few of these combinations have produced unacceptable 
hepatic toxicity [82, 83], the use of the combinations of PD-1 pathway inhibitors with more 
selective inhibitors of the VEGF pathway (e.g., atezolizumab with bevacizumab, pembroli-
zumab with axitinib, or avelumab with axitinib) has proven to be more tolerable [55, 84–87]. 
Preliminary results from studies combining immune checkpoints and VEGF pathway inhibi-
tors have shown encouraging clinical activity in terms of PFS and ORR [83–86]. In an ongoing 
phase Ib study of 52 treatment-naïve patients, pembrolizumab plus axitinib resulted in an 
ORR of 67%, including 2 complete responses and 33 PR; median PFS is not yet mature, with 7 
patients of 11 enrolled in the dose-finding phase remaining progression-free at 11 months [84]. 
Smaller phase I studies evaluating avelumab plus axitinib and pembrolizumab plus pazo-
panib combination therapy reported ORRs of 83% (5 PRs of 6 treated patients) and 60% (6 of 
10 patients; pazopanib 800 mg cohort), respectively [47, 85]. Atezolizumab plus bevacizumab 
combination therapy in 10 previously untreated patients with mRCC also resulted in clinical 
benefits (4 patients with PRs and 4 with stable disease) [86]. Confirmatory randomized phase 
III trials comparing sunitinib versus either atezolizumab with bevacizumab (NCT02420821), 
avelumab with axitinib (NCT02684006), or pembrolizumab with axitinib (NCT02853331) are 
ongoing. Preclinical data from an RCC mouse model showed that radiation enhanced the 
therapeutic effect of IL-2 immunotherapy on pulmonary metastases [88]. One explanation is 
that DCs are recruited to the irradiated site when radiotherapy is applied in few-fraction and 
high-dose manners [89]. Currently, a clinical trial evaluating the combination of radiation 
therapy with pembrolizumab for patients with recurrent or mRCC is ongoing (NCT02318771).
Therefore, a number of combination strategies, such as PD-1/PD-L1 blockade, PD-1 antibody 
with other immunotherapeutic agents, PD-1 antibody with antiangiogenesis agents, and 
combination with radiotherapy, are currently in clinical trial research to determine whether 
there is a most favorable sequence of treatment and if combination strategy benefits mRCC 
patients. Results from recent clinical trials with immunotherapeutic agents suggest that 
immunotherapy in combination with other agents is capable of producing durable responses 
and significant overall survival improvement. Thus, in the future, immunotherapy, together 
with other treatments, will likely cause a paradigm shift in the clinical management of mRCC 
patients. However, the combination of immunotherapeutic agents does have considerable 
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toxicities such as gastrointestinal and hepatic toxicities, and careful patient selection must 
be guaranteed [90, 91]. Therefore, much more studies must be taken to define the role of 
combination treatment with immunotherapy agents in mRCC. Moreover, further studies are 
warranted to identify biomarkers that reliably predict the treatment benefit from these new 
therapies.
Checkpoint inhibitor Targeted therapy Phase Population Identifier
Nivolumab Sunitinib
Pazopanib
I Advanced RCC, 
prior cytokine 
therapy allowed
NCT01472081 (CheckMate 
016)
Atezolizumab Bevacizumab Ib Untreated, 
advanced clear cell 
RCC
NCT01633970
Nivolumab Bevacizumab Neoadjuvant pilot Metastatic clear cell 
RCC, prior therapy 
allowed
NCT02210117
Nivolumab Temsirolimus Ib/II Metastatic RCC, 
prior therapy 
allowed
NCT02423954
Pembrolizumab Pazopanib I/II Untreated, 
advanced clear cell 
RCC
NCT02014636
Pembrolizumab Axitinib Ib Untreated, 
advanced clear cell 
RCC
NCT02133742
Pembrolizumab Bevacizumab Ib/II Metastatic clear cell 
RCC treated with 
failure of at least 
one prior therapy
NCT02348008
Pembrolizumab Aflibercept I Metastatic RCC 
treated with at least 
one prior VEGF TKI
NCT02298959
Avelumab Axitinib Ib Untreated, 
advanced clear cell 
RCC
NCT02493751
Atezolizumab Bevacizumab III Untreated, 
advanced clear cell 
RCC
NCT02420821
Avelumab Axitinib III Untreated, 
advanced clear cell 
RCC
NCT02684006
Pembrolizumab Axitinib III Untreated, 
advanced clear cell 
RCC
NCT02853331 (MK-3475-426/
KEYNOTE-426)
RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
Table 2. Ongoing immune checkpoint inhibitor and targeted therapy combinational trials in RCC.
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7. Adjuvant and neoadjuvant immunotherapy
With the promising outcome of immunotherapy in mRCC, it is reasonable to explore whether 
immunotherapy works in the non-metastatic adjuvant setting. Noteworthy, spontaneous 
antitumor immune infiltration was shown to be higher in primary tumors with respect to 
matched metastases [92], suggesting that the administration of immunotherapy in the early 
setting might be more effective than in the advanced setting. However, trials of adjuvant 
therapy involving tumor cell vaccination, IFN-α, or HD IL-2 have not shown survival benefits 
[93]. Trials studying the role of checkpoint inhibition (anti PD-1/PD-L1 agents) are proceed-
ing, and the results are eagerly awaited. Studies are also under way to determine the fea-
sibility of ICIs as neoadjuvant (nivolumab, NCT02575222, NCT02595918; durvalumab with 
or without tremelimumab, NCT02762006) or adjuvant therapy (nivolumab; NCT02595944, 
NCT02388906, NCT02743494, NCT02632409; pembrolizumab, NCT02362594, NCT02504372; 
atezolizumab, NCT02450331, NCT02927301, NCT02912559, NCT02486718). We believe that a 
big movement in RCC management will occur if we can find a way to increase survival rates 
in the adjuvant or neoadjuvant setting of surgically managed patients.
8. Non-clear cell RCC (nccRCC)
Non-clear cell histology constitutes 20–25% of RCCs [94, 95]. However, this group is hetero-
geneous, and individually each subtype is relatively rare and thus difficult to study in large 
prospective trials. nccRCC includes papillary, chromophobe, sarcomatoid, collecting duct, 
medullary, and various hereditary forms, among which papillary is the most common sub-
type [94]. Patients with metastatic nccRCC have generally proven to be less responsiveness to 
the drugs shown to be active in ccRCC [96]. Although some patients with nccRCC may obtain 
some benefit from VEGF-targeting TKIs, retrospective studies have generally suggested that 
these agents have inferior efficacy compared with what would be expected in patients with 
ccRCC [97]. This was also true in the previous era of immunotherapy HD IL-2. Although 
included in some of the large trials of HD IL-2, patients with nccRCC rarely experienced 
clinical benefits [95, 98, 99]. Treatment with IFN-α has also showed limited efficacy in patients 
with non-clear cell histology [95]. No prospective data currently exist to characterize the 
response of patients with nccRCC to ICIs, though several case reports have been published 
identifying single responses across various histologies [100–102]. Several ongoing studies are 
evaluating ICIs as a single agent or in combination in patients with nccRCC.
9. Therapy response and predictive biomarkers
The use of immunotherapies for RCC provides evidence that immune-based treatments can 
drastically improve survival or antitumor effects for patients with advanced RCC. However, 
only certain patients obtain clinic benefit as a durable response, so we need to identify reliable 
predictive biomarkers of treatment response to optimize patient selection.
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The evaluation of responses to immunotherapeutic agents represents a challenge in the clinic. 
Specific tumor response patterns with ICI treatment sometimes differ from those with chemo-
therapeutic and targeted agents. Due to immune-mediated mechanisms, tumor flare, which 
shows enlarged size of baseline lesions or increased total tumor burden, may occur before 
cellular immune responses have a chance to affect the actual tumor size [103]. Additionally, 
transient immune cell infiltration at the tumor site may boost the appearance of tumor growth 
[103, 104]. Therefore, tumor flare can confuse tumor response interpretation by appearing as 
disease progression, hence the term pseudoprogression, and may result in inappropriately 
switching therapy before ongoing clinical benefits manifest on imaging [105]. While pseudo-
progression is relatively uncommon (occurring in <10% of patients) versus true progression, 
it sometimes presents a challenge for patients and for clinicians in determining when to stop 
and/or switch therapy [105]. Recently updated guidelines for the use of modified RECIST 
(iRECIST) in trials of immunotherapies were published in an effort to standardize and validate 
these criteria and harmonize the interpretation of the results [106].
Response to ICI has been associated with specific intrinsic and extrinsic properties of tumors 
or of the host that have been recently classified as the elements of the cancer-immune set point 
[107]. Intrinsic properties reflect the degree of tumor foreignness [108], linked to the muta-
tional burden and the presence of neoantigens that can be recognized by the immune system, 
as shown in NSCLC and melanoma [109, 110]. Foreignness of RCC might vary by molecular 
subtype and a higher number of mutations [111]. In addition, the general individual immune 
status, mirrored by the levels of circulating lymphocytes and the neutrophil to lymphocyte 
ratio (NLR), the increase of the C reactive protein, the erythrocyte sedimentation rate PD-L1 
expression (although controversial), and LDH were shown to influence the response to ICI.
In addition to the intrinsic properties of the tumors, extrinsic factors, such as exposure to sun-
light and to cigarette smoke, the presence of viral infections, and the composition of the gut 
microbiota, were classified as elements of the cancer-immune set point [107]. The exposure to 
sunlight and cigarette smoke was relevant for melanoma and NSCLC, respectively, while the 
presence of viral infections might impact the response to ICI in human papilloma virus posi-
tive tumors and Epstein-Barr virus related tumors. Preclinical evidence showed that several 
bacteroides and bifidobacterium species influenced the efficacy of ICI with anti-CTLA-4 and 
anti-PD-L1 mAb in mice [112–114]. The role of the gut microbiota in patients with renal cancer 
treated with ICB requires further investigations.
Taken together, these data suggest that multiple parameters should be taken into account to 
identify ideal candidates for immunotherapy in RCC. The genomic landscape likely has a role 
in determining the putative immunogenicity of the tumor [115]; TIL, PD-L1 expression, and 
immune gene signatures could detect tumors with an inflamed phenotype, which have higher 
chances of response to ICB [107, 116].
10. Perspective
The advent of immunotherapy has brought about a paradigm shift in the treatment of 
advanced RCC. Properly integrating immunotherapy into the present treatment is challenging. 
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Preclinical research has demonstrated the role of VEGF in suppressing tumor immune 
responses—an attractive strategy to combine with ICIs [117–119]. This successful synergy has 
been confirmed in phase 1 and 2 studies with axitinib-pembrolizumab [84], axitinib-avelumab 
[120], lenvatinib-pembrolizumab [121], and bevacizumab-atezolizumab [122, 123]. The ORR 
ranged between 32% and 67%, and AEs were manageable in all these studies, in contrast to 
studies in other combinations as TKIs (pazopanib/sunitinib) plus immunotherapy, which did 
not move forward because of unacceptable toxicity [83, 124, 125]. Although preliminary, the 
abovementioned results are encouraging and have led to larger, confirmatory, phase 3 trials, 
which are now actively accruing patients.
In addition, different novel immunotherapies beyond ICIs are being investigated, including 
adoptive T-cell therapy and T-cell agonists.
Adoptive T-cell transfer therapy refers to the autologous or allogeneic infusion of T-cells. One 
such therapy involves the generation and infusion of chimeric antigen receptor (CAR) T-cells—T 
cells that have been genetically modified to express a receptor specific to tumor epitopes inde-
pendent of HLA. The promising efficacy of anti-CD19 CAR T cells in hematological malignan-
cies has inspired further investigations in solid tumors [126]. One of the key aspects of designing 
effective CAR T cells is finding a tumor-associated antigen that is uniformly expressed in tumor 
cells but not in the normal tissue. Carbonic anhydrase 9 (CAIX) is an enzyme that is overex-
pressed in clear-cell RCC but minimally expressed in normal tissue [127]. Early efforts in using 
CAIX as a tumor-associated antigen for CAR resulted in liver enzyme elevations that limited its 
use, likely owing to the therapy also targeting CAIX expressed in the liver bile duct epithelium 
[128]. Cor H.J. Lamers and his colleagues gave patients a CAIX monoclonal antibody before 
infusion of CAR T cells to reduce this off-target toxicity [129]. However, in the study, no clinical 
responses were observed, and the efficacy of CAIX CAR T cells is yet to be proven.
Another form of adoptive immune cell therapy tested in RCC is autologous cytokine-induced 
killer (CIK) cell immunotherapy. CIK cells are created in vitro by harvesting peripheral mono-
nuclear cells in the blood using an anti-CD3 antibody. The resulting phenotype by IL-1, IFNγ, 
and IL-2 shares features of effector T-cells and natural killer cells [130]. A phase II trial ran-
domly assigned 148 patients with mRCC to CIK cell immunotherapy or IL-2 combined with 
IFNα [131]. PFS and OS at 3 years in the CIK cell therapy arm were 18% and 61%, respectively, 
compared with 12% and 23% in the IL-2 plus IFNα arm (p = 0.031 and p < 0.001, respectively). 
This therapy is being further investigated in conjunction with DC vaccines and early results 
show that therapy is well tolerated and might have activity against RCC [132].
Stimulatory molecules expressed on immune cells can also be targeted with agonist antibod-
ies. CD137 is a co-stimulatory molecule for T-cells that increases T-cell effector activity and 
survival. Its use in combination with anti-DR5 and anti-CD40 antibodies in mouse models of 
RCC has shown to improve survival compared with control mice (p < 0.001) [133]. The CD137 
agonist PF-05082566 is currently being tested in combination with pembrolizumab in a phase 
I trial of advanced solid tumors, including RCC (NCT02179918). Varlilumab is an agonist anti-
body targeting CD27, another co-stimulatory molecule for T-cell activation. In a phase I trial 
in solid tumors, including 11 patients with RCC, of the six evaluable RCC patients, two had 
stable diseases [134]. This antibody is currently being studied in combination with sunitinib 
and in combination with atezolizumab in phase I/II trials in RCC (NCT02386111).
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In addition to CD137 and CD27, other co-stimulatory molecules such as OX40 and GITR are 
also promising therapeutic targets. Trials of monotherapy with the OX40 agonist MEDI0562, 
and with the GITR agonists MK-4166 and TRX518, are under way in solid tumor malignancies 
(NCT02318394, NCT02132754, and NCT02628574). Like combination checkpoint blockade 
strategies, much enthusiasm exists for combined treatment strategies with other immuno-
modulatory agents [135, 136].
Owing to the unique antitumor mechanisms elicited by immunotherapy, patients treated with 
these agents can have tumor response patterns that are different from conventional tumor-
response criteria, such as the WHO criteria [137, 138]. A subset of patients receiving ICI ther-
apy develop pseudoprogression, in which tumor burden decreases after an initial increase or 
during or after the appearance of new lesions. The evaluation of pseudoprogression provides 
new challenges in treatment monitoring and therapeutic decision-making because it cannot 
be evaluated with the existing response-evaluation criteria. The establishment of a standard-
ized strategy to evaluate immune-related responses in patients receiving ICIs is extremely 
important. However, advances in the knowledge of immune-related responses have been 
challenged by the fact that only a few clinical trials have used the immune-related response 
criteria (irRC) [103] or immune-related response evaluation criteria in solid tumors (irRE-
CIST) [139] as the primary criteria to define their end points [77, 104, 140].
In addition, the development of robust biomarkers to assist prediction of response and clini-
cal benefits of immunotherapy is essential to further advance the field as precision immuno-
oncology. Despite the remarkable success of clinical applications of immunotherapy reported 
in the past decade, the effectiveness of these therapies varies greatly across individual patients 
and among different tumor types. A substantial unmet need is the development of biomark-
ers of response to immunotherapeutic agents, in order to identify, before the initiation of 
treatment, which patients are likely to experience clinical benefit from such treatments. This 
aspect is particularly important in the management of tumors with low response rates, such 
as NSCLC (response rate ≤ 20%), RCC, and urothelial carcinoma (UCC) [141]. The growing 
knowledge of molecular subtypes of RCC with next-generation sequencing is the first step 
toward developing RCC-specific genomic signatures and guiding therapy selection, thereby 
moving toward precision medicine [142].
Taken together, the therapeutic activity of immunotherapy is the result of a complex interplay 
between multiple factors in the tumor, tumor microenvironment, and immune system, requir-
ing a collaborative approach to translate the emerging knowledge into the clinical context.
11. Conclusions
Novel immune therapies are emerging as an important addition to targeted therapies in the 
treatment of RCC. Many questions regarding their use remain to be optimized including dose, 
schedule, AEs, and adjuvant or neoadjuvant application. An investigation of the rational com-
bination of different treatment modalities is also critical in maximizing the potential of immu-
notherapy. Additional investigations into predictive biomarkers or resistance mechanisms are 
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needed to optimize patient selection. To date, nivolumab has been approved in the second-
line setting, and randomized phase III trials with novel immunotherapy combinations are 
challenging the first-line standard of care in RCC—in the near future, immunotherapy will 
likely be a new standard therapy.
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